You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

Article info

Article menu
Case report
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

Authors

  • Luke Frankiw Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Arun Singh Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Cole Peters Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Begoña Comin-Anduix Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, USAJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Beata Berent-Maoz Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Mignonette Macabali Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Kiana Shammaie Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Crystal Quiros Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Paula Kaplan-Lefko Department of Medicine, Division of Pediatric Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Ignacio Baselga Carretero Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Antoni Ribas Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, USAJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USADepartment of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USAEli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California, USA PubMed articlesGoogle scholar articles
  • Theodore Scott Nowicki Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of California Los Angeles, Los Angeles, California, USAJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USAEli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California, USADepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, California, USAMolecular Biology Institute, University of California Los Angeles, Los Angeles, CA, USA PubMed articlesGoogle scholar articles

Citation

Frankiw L, Singh A, Peters C, et al
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
Journal for ImmunoTherapy of Cancer 2023;11:e006930. doi: 10.1136/jitc-2023-006930
Online issue publication 
May 08, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.